James Smith, Semaglutide and What the Clinical Evidence Shows

What the STEP 1 trial found, and why that number needs context

The most-cited figure from the semaglutide evidence base comes from the STEP 1 trial, a phase-3 study involving 1,961 adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. Over 68 weeks, participants taking weekly semaglutide 2.4mg alongside lifestyle support lost an average of roughly 15% of their body weight, compared with about 2.4% in the placebo group. That result, published in the New England Journal of Medicine, is what underpins the UK licence and NICE's recommendation for Wegovy.

The number that tends to circulate on social media is sometimes the best-responder figure rather than the trial average. Both are real; they measure different things. The average is what you would expect across a wide population. Individual responses vary considerably, shaped by starting weight, metabolic profile, adherence to lifestyle changes, and how well the medicine is tolerated at each dose. That variation is not a flaw, it reflects the reality of any medical treatment.

A common misconception is that the weight lost returns the moment treatment ends and is therefore pointless. Regain after stopping is real and well-documented, but that does not make the treatment ineffective, it reflects the biology of obesity as a chronic condition, not a character failing. Clinicians discuss continuation and long-term planning as part of any supervised programme.

How semaglutide works, and where James Smith's commentary fits

Semaglutide mimics a gut hormone called GLP-1, which is released naturally after eating. It slows how quickly the stomach empties, signals the brain to reduce appetite, and influences blood-sugar regulation. The result, for most people, is a substantial and sustained reduction in calorie intake without requiring active restriction at every meal. You can read a fuller explanation on the semaglutide overview page.

James Smith's public commentary on semaglutide, including sceptical views about dependency and criticism of it as a substitute for lifestyle change, reflects a debate that is genuinely happening in clinical circles too. The established position from bodies including NHS England is that these medicines work best alongside, not instead of, reduced-calorie eating and increased activity. That is also how the trials were designed. What the evidence does not support is the idea that the drug is simply a shortcut for people unwilling to do the work. Most people who reach a BMI of 35 or above have already tried conventional approaches repeatedly.

If you want to explore the various names semaglutide goes under in the UK, our guide covers both the weight-management and diabetes-licensed products clearly.

What UK eligibility for semaglutide actually looks like

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of semaglutide (TA875). NICE's recommendation applies to NHS access only; private eligibility follows the licensed indications in the SmPC.

On the NHS, Wegovy is available through specialist weight management services under TA875, which specifies a maximum treatment duration of two years and requires multidisciplinary support. Waiting lists at those services are often long, and not everyone who meets the criteria gets prompt access. Private treatment through a regulated pharmacy is the route that does not involve a referral queue, though the clinical bar for suitability remains the same. Our Wegovy treatment page explains both routes and what the consultation process looks like.

Cost is a fair consideration. Private semaglutide treatment varies by dose and provider; since Eli Lilly's list-price adjustment in September 2025 pushed up Mounjaro pricing, the relative positioning of Wegovy has shifted slightly too. For a clear picture of what private treatment actually costs, the Wegovy pricing page sets out what a legitimate private prescription typically includes.

Side effects, the 'hangover' question, and what to do if something feels wrong

The side-effect profile of semaglutide is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, reflux and burping are the most common. These tend to peak in the day or two after each injection, which is why some people describe a weekly semaglutide hangover. The semaglutide hangover page covers this pattern in more detail, including practical ways to reduce it.

Most GI symptoms settle as the body adjusts, particularly after a few weeks at a new dose. Starting at the 0.25mg tolerability dose and titrating slowly is specifically designed to reduce this burden, a prescriber manages the pace based on how you are tolerating each step. Serious but less common side effects include pancreatitis. The MHRA highlighted acute pancreatitis as a known risk in a January 2026 Drug Safety Update: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Gallbladder issues, allergic reactions and dehydration from sustained vomiting are also reasons to seek help promptly rather than wait.

The NHS patient information for semaglutide is the most accessible reference for a complete side-effect list, and patients can report any suspected reaction directly via the MHRA Yellow Card scheme. You can also contact the nume support team seven days a week if you are already in treatment and something does not feel right.